Giovanna R Mallucci

List of Publications by Citations

50 papers	4,299 citations	30 h-index	61 g-index
61 ext. papers	5,135 ext. citations	11.7 avg, IF	5.56 L-index

#	Paper	IF	Citations
50	Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. *Science*, **2003**, 302, 871-4	33.3	578
49	Sustained translational repression by eIF2P mediates prion neurodegeneration. *Nature*, **2012**, 485, 507-11	50.4	445
48	Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice. *Science Translational Medicine*, **2013**, 5, 206ra138	17.5	393
47	Post-natal knockout of prion protein alters hippocampal CA1 properties, but does not result in neurodegeneration. *EMBO Journal*, **2002**, 21, 202-10	13	290
46	Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing. *Nature Reviews Drug Discovery*, **2018**, 17, 660-688	64.1	232
45	Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice. *Neuron*, **2007**, 53, 325-35	13.9	204
44	Partial restoration of protein synthesis rates by the small molecule ISRIB prevents neurodegeneration without pancreatic toxicity. *Cell Death and Disease*, **2015**, 6, e1672	9.8	184
43	PERK inhibition prevents tau-mediated neurodegeneration in a mouse model of frontotemporal dementia. *Acta Neuropathologica*, **2015**, 130, 633-42	14.3	169
42	Repurposed drugs targeting eIF2α-P-mediated translational repression prevent neurodegeneration in mice. *Brain*, **2017**, 140, 1768-1783	11.2	159
41	Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 10238-43	11.5	137
40	RBM3 mediates structural plasticity and protective effects of cooling in neurodegeneration. *Nature* , **2015**, 518, 236-9	50.4	127
39	Nerve injury induces robust allodynia and ectopic discharges in Nav1.3 null mutant mice. *Molecular Pain*, **2006**, 2, 33	3.4	119
38	Mitofusin-mediated ER stress triggers neurodegeneration in pink1/parkin models of Parkinson's disease. *Cell Death and Disease*, **2016**, 7, e2271	9.8	105
37	Enhancing nucleotide metabolism protects against mitochondrial dysfunction and neurodegeneration in a PINK1 model of Parkinson's disease. *Nature Cell Biology*, **2014**, 16, 157-66	23.4	91
36	The unfolded protein response: mechanisms and therapy of neurodegeneration. *Brain*, **2016**, 139, 2113-21	11.2	83
35	Targeting the unfolded protein response in neurodegeneration: A new approach to therapy. *Neuropharmacology*, **2014**, 76 Pt A, 169-74	5.5	80
34	The unfolded protein response in neurodegenerative disorders - therapeutic modulation of the PERK pathway. *FEBS Journal*, **2019**, 286, 342-355	5.7	74

33	Astrocyte Unfolded Protein Response Induces a Specific Reactivity State that Causes Non-Cell-Autonomous Neuronal Degeneration. *Neuron*, **2020**, 105, 855-866.e5	13.9	73
32	Rational targeting for prion therapeutics. *Nature Reviews Neuroscience*, **2005**, 6, 23-34	13.5	72
31	Review: Modulating the unfolded protein response to prevent neurodegeneration and enhance memory. *Neuropathology and Applied Neurobiology*, **2015**, 41, 414-27	5.2	56
30	Neuronal Mitochondrial Dysfunction Activates the Integrated Stress Response to Induce Fibroblast Growth Factor 21. *Cell Reports*, **2018**, 24, 1407-1414	10.6	51
29	Prion neurodegeneration: starts and stops at the synapse. *Prion*, **2009**, 3, 195-201	2.3	46
28	Prions: generation and spread versus neurotoxicity. *Journal of Biological Chemistry*, **2014**, 289, 19862-8	5.4	45
27	The UPR and synaptic dysfunction in neurodegeneration. *Brain Research*, **2016**, 1648, 530-537	3.7	43
26	Small Molecules to Improve ER Proteostasis in Disease. *Trends in Pharmacological Sciences*, **2019**, 40, 684-695	13.2	41
25	M1 muscarinic allosteric modulators slow prion neurodegeneration and restore memory loss. *Journal of Clinical Investigation*, **2017**, 127, 487-499	15.9	39
24	Noncanonical Modulation of the eIF2 Pathway Controls an Increase in Local Translation during Neural Wiring. *Molecular Cell*, **2019**, 73, 474-489.e5	17.6	39
23	RTN3 Is a Novel Cold-Induced Protein and Mediates Neuroprotective Effects of RBM3. *Current Biology*, **2017**, 27, 638-650	6.3	32
22	Fine-tuning PERK signaling for neuroprotection. *Journal of Neurochemistry*, **2017**, 142, 812-826	6	31
21	miRNAs-19b, -29b-2* and -339-5p show an early and sustained up-regulation in ischemic models of stroke. *PLoS ONE*, **2013**, 8, e83717	3.7	30
20	Control of translation elongation in health and disease. *DMM Disease Models and Mechanisms*, **2020**, 13,	4.1	30
19	Targeting synaptic pathology with a novel affinity mass spectrometry approach. *Molecular and Cellular Proteomics*, **2014**, 13, 2584-92	7.6	22
18	Nitric oxide-mediated posttranslational modifications control neurotransmitter release by modulating complexin farnesylation and enhancing its clamping ability. *PLoS Biology*, **2018**, 16, e2003611	9.7	20
17	The role of GPI-anchored PrP C in mediating the neurotoxic effect of scrapie prions in neurons. *Current Issues in Molecular Biology*, **2010**, 12, 119-27	2.9	20
16	Cooling-induced SUMOylation of EXOSC10 down-regulates ribosome biogenesis. *Rna*, **2016**, 22, 623-35	5.8	19

15	Therapy for prion diseases: Insights from the use of RNA interference. *Prion*, **2009**, 3, 121-8	2.3	18
14	Rescuing neurons in prion disease. *Biochemical Journal*, **2011**, 433, 19-29	3.8	17
13	Update on Creutzfeldt-Jakob disease. *Current Opinion in Neurology*, **2004**, 17, 641-7	7.1	17
12	RNAi for the treatment of prion disease: a window for intervention in neurodegeneration?. *CNS and Neurological Disorders - Drug Targets*, **2009**, 8, 342-52	2.6	14
11	Dysfunction and recovery of synapses in prion disease: implications for neurodegeneration. *Biochemical Society Transactions*, **2010**, 38, 482-7	5.1	12
10	Spreading proteins in neurodegeneration: where do they take us?. *Brain*, **2013**, 136, 994-5	11.2	9
9	Developing Therapies for Neurodegenerative Disorders: Insights from Protein Aggregation and Cellular Stress Responses. *Annual Review of Cell and Developmental Biology*, **2020**, 36, 165-189	12.6	8
8	Translating translation in Down syndrome. *Science*, **2019**, 366, 797-798	33.3	4
7	Targeted knock-down of cellular prion protein expression in myelinating Schwann cells does not alter mouse prion pathogenesis. *Journal of General Virology*, **2013**, 94, 1435-1440	4.9	4
6	Targeting the kinase insert loop of PERK selectively modulates PERK signaling without systemic toxicity in mice. *Science Signaling*, **2020**, 13,	8.8	4
5	Cognitive Impairment and Dementia245-288		3
4	TrkB signaling regulates the cold-shock protein RBM3-mediated neuroprotection. *Life Science Alliance*, **2021**, 4,	5.8	3
3	Neuropsychiatric presentations of prion disease. *Current Opinion in Psychiatry*, **1997**, 10, 59-62	4.9	2
2	Reply: Trazodone to change the risk of neurodegeneration: bedside to bench. *Brain*, **2017**, 140, e48	11.2	1
1	Modeling Huntington Disease in Yeast and Invertebrates **2015**, 557-572		